The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
AbstractBackground Despite the widespread use of classical cholesterol-lowering drugs to mitigate the adverse impacts of dyslipidaemia on atherosclerosis, many patients still face a substantial residual risk of developing atherosclerotic cardiovascular disease (CVD). This risk is partially attribute...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2024.2304667 |
| _version_ | 1827346544600285184 |
|---|---|
| author | Panagiotis Stachteas Paschalis Karakasis Dimitrios Patoulias Francesco Clemenza Nikolaos Fragakis Manfredi Rizzo |
| author_facet | Panagiotis Stachteas Paschalis Karakasis Dimitrios Patoulias Francesco Clemenza Nikolaos Fragakis Manfredi Rizzo |
| author_sort | Panagiotis Stachteas |
| collection | DOAJ |
| description | AbstractBackground Despite the widespread use of classical cholesterol-lowering drugs to mitigate the adverse impacts of dyslipidaemia on atherosclerosis, many patients still face a substantial residual risk of developing atherosclerotic cardiovascular disease (CVD). This risk is partially attributed to non-traditional pathophysiological pathways. Latest evidence suggests that sodium glucose co-transporter-2 (SGLT2) inhibitors are beneficial for patients suffering from type 2 diabetes mellitus (T2DM) or established CVD by reducing morbidity and mortality. However, the underlying mechanisms of this benefit have not been clearly elucidated. It has been hypothesized that one possible mechanism could be the attenuation of subclinical atherosclerosis (SA) progression.Aim The objective of this narrative review is to examine the present evidence concerning the impact of SGLT2 inhibitors on markers of SA.Results The current evidence on the efficacy of SGLT2 on SA, endothelial function and arterial stiffness remains controversial. Findings from observational and randomized studies are quite heterogeneous; however, they converge that the antiatherosclerotic activity of SGLT2 inhibitors is not strong enough to be widely used for prevention of atherosclerosis progression in patients with or without T2DM.Conclusions Further research is needed to investigate the underlying mechanisms and the possible beneficial impact of SGLT2i on primary and secondary CVD prevention through attenuation of premature atherosclerosis progression. |
| first_indexed | 2024-03-07T23:32:44Z |
| format | Article |
| id | doaj.art-7ee17732788640c4b6f69f05c356236c |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-07T23:32:44Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-7ee17732788640c4b6f69f05c356236c2024-02-20T11:58:24ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602023-12-0155210.1080/07853890.2024.2304667The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosisPanagiotis Stachteas0Paschalis Karakasis1Dimitrios Patoulias2Francesco Clemenza3Nikolaos Fragakis4Manfredi Rizzo5Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSecond Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, GreeceOutpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, GreeceDepartment for the Study and Treatment of Cardiothoracic Diseases and for Cardiothoracic Transplants, Cardiology Unit, IRCCS – ISMETT, Palermo, ItalySecond Department of Cardiology, Aristotle University of Thessaloniki, Thessaloniki, GreeceMohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab EmiratesAbstractBackground Despite the widespread use of classical cholesterol-lowering drugs to mitigate the adverse impacts of dyslipidaemia on atherosclerosis, many patients still face a substantial residual risk of developing atherosclerotic cardiovascular disease (CVD). This risk is partially attributed to non-traditional pathophysiological pathways. Latest evidence suggests that sodium glucose co-transporter-2 (SGLT2) inhibitors are beneficial for patients suffering from type 2 diabetes mellitus (T2DM) or established CVD by reducing morbidity and mortality. However, the underlying mechanisms of this benefit have not been clearly elucidated. It has been hypothesized that one possible mechanism could be the attenuation of subclinical atherosclerosis (SA) progression.Aim The objective of this narrative review is to examine the present evidence concerning the impact of SGLT2 inhibitors on markers of SA.Results The current evidence on the efficacy of SGLT2 on SA, endothelial function and arterial stiffness remains controversial. Findings from observational and randomized studies are quite heterogeneous; however, they converge that the antiatherosclerotic activity of SGLT2 inhibitors is not strong enough to be widely used for prevention of atherosclerosis progression in patients with or without T2DM.Conclusions Further research is needed to investigate the underlying mechanisms and the possible beneficial impact of SGLT2i on primary and secondary CVD prevention through attenuation of premature atherosclerosis progression.https://www.tandfonline.com/doi/10.1080/07853890.2024.2304667SGLT-2 inhibitorsFMDPWVIMTarterial stiffnessendothelial dysfunction |
| spellingShingle | Panagiotis Stachteas Paschalis Karakasis Dimitrios Patoulias Francesco Clemenza Nikolaos Fragakis Manfredi Rizzo The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis Annals of Medicine SGLT-2 inhibitors FMD PWV IMT arterial stiffness endothelial dysfunction |
| title | The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis |
| title_full | The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis |
| title_fullStr | The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis |
| title_full_unstemmed | The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis |
| title_short | The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis |
| title_sort | effect of sodium glucose co transporter 2 inhibitors on markers of subclinical atherosclerosis |
| topic | SGLT-2 inhibitors FMD PWV IMT arterial stiffness endothelial dysfunction |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2024.2304667 |
| work_keys_str_mv | AT panagiotisstachteas theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT paschaliskarakasis theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT dimitriospatoulias theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT francescoclemenza theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT nikolaosfragakis theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT manfredirizzo theeffectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT panagiotisstachteas effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT paschaliskarakasis effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT dimitriospatoulias effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT francescoclemenza effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT nikolaosfragakis effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis AT manfredirizzo effectofsodiumglucosecotransporter2inhibitorsonmarkersofsubclinicalatherosclerosis |